Skip to content

Clinical Evaluation of MyoCare in Europe (CEME)

Clinical Evaluation of MyoCare in Europe (CEME): Study Protocol for a Prospective, Multicenter, Randomized, Double-blinded, and Controlled Clinical Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05919654
Acronym
CEME
Enrollment
300
Registered
2023-06-26
Start date
2022-09-15
Completion date
2025-07-31
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia, Progressive

Keywords

myopia

Brief summary

A 2-year prospective, multicenter, randomized controlled, and double-blind clinical trial is used to investigate the efficacy of a new design of ophthalmic lenses to slow the progression of myopia. 300 children aged from 6 to 13 years old will be recruited and randomly assigned to a study or control group. The study group will be composed of 150 children wearing MyoCare while the control group will be composed of 150 children wearing Clearview. The inclusion criteria will be myopia with a spherical equivalent between -0.75D and -5.00D, astigmatism \< 1.50D, and anisometropia \< 1.00D, as well as having a historical evolution of at least -0.50 The primary outcome is to compare the mean annual progression of the spherical equivalent between both groups. The secondary outcomes are axial length, choroidal thickness, phorias, and accommodative status of both groups.

Interventions

DEVICEMyoCare

Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.

DEVICEClearView

Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.

Sponsors

Cooperativa de Ensino Superior, Politécnico e Universitário
CollaboratorOTHER
Novovision
CollaboratorUNKNOWN
Instituto de Cirugia Ocular
CollaboratorOTHER
Miranza Virgen de Lujan
CollaboratorUNKNOWN
ICQO Instituto Quirúrgico de Oftalmología
CollaboratorUNKNOWN
CPO Clinica Privada de Oftalmologia, S.A.
CollaboratorUNKNOWN
Carl Zeiss Vision International GmbH
CollaboratorUNKNOWN
Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 13 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 6-13 years * Caucasian ethnicity * Monocular/binocular decimal visual acuity with correction ≥ 1.00 * Spherical equivalent between -0.75D and -5.00D * Astigmatism \< 1.50D * Anisometropia \< 1.00D * Evolution of at least -0.50D in one year

Exclusion criteria

* Presence of ocular pathology or a history of ocular and systemic abnormalities * Strabismus or binocular vision problems * History of eye surgery * Having previously used some method to control myopia. * Having contraindications for the application of drugs for cycloplegia/corneal anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Objective refraction2 yearsObjective refraction will be taken after cycloplegia as the mean of 3 measurements with the i.profiler (Carl Zeiss Meditec AG, Jena, Germany) autorefractometer. The mean annual progression of the objective refraction will be compared between myopic children treated with ZEISS MyoCare lenses and those who wear a conventional single-vision lens.

Secondary

MeasureTime frameDescription
Axial length2 years1\. To compare the mean annual progression of axial length between myopic children treated with ZEISS MyoCare lenses and those who wear a conventional single-vision lens.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026